October #117 : Seeking for the Perfect Pill - by Ivan Oransky MD

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Immuno's Defense

Quick Draw




The Common Touch

Seeking for the Perfect Pill

Three’s the Charm With One-A-Day

No Cure, But A Better Liver

Striking Gold

Doctor’s Diary - October 2005

Home Work

Daring to Diet

Do and Don’t-Do Diets

Flu-Shot Time

Smokin’!

In Sickness and In Health

Buzz Off

A Little off the Top

Buddy Up




Who Will Save Them Next?

Pulse - October 2005

Wait-Lifting Stretches

Charlize in Charge

Miss Congeniality 3:HIV

Rap Sheet

Mentors - October 2005

Sex Toys R Us

Trying Trials

Underexposed




Editor's Letter - October 2005

Mailbox - October 2005



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV



email print

October 2005


Seeking for the Perfect Pill

by Ivan Oransky MD

Will two new meds solve the problem with protease?

As HIV’s powerful protease inhibitors (PIs) hit their 10th birthday, meet the two new kids who bring the PI class size to 10: Aptivus (tipranavir), FDA-approved in June, and TMC-114, heading for approval. Both have unique resistance profiles, battling HIV that evades other PIs. And a recent study suggests that combining TMC-114 and Norvir (ritonavir) downs HIV better than other Norvir-boosted PIs. “Both new drugs seem very powerful,” says Howard Grossman, MD, executive director of the American Academy of HIV Medicine. “Efficacy against resistant virus is important.” TMC-114 is being tested in both new and veteran med takers, while Grossman says Aptivus has targeted mostly “the deep salvage arena.”

But the two pills are perfect examples of, well, the perennially imperfect PI class. Neither skirts the PI weakness of raising lipids (blood fats), and both need a boost from the handy PI helper Norvir—which comes with its own side effects. The body breaks down Norvir via the same liver enzyme as the other PIs, so adding Norvir forces the others to hang around and work longer. No HIVer who has benefited from a Norvir-boosted combo would knock it, but the capsule’s chronic gastrointestinal (GI) and lipid issues leave some longing to lose it. Most PIs need 100 milligrams of Norvir once or twice daily, but Marshall Glesby, MD, of Cornell’s Weill Medical College, says Aptivus needs a whopping 200 milligrams twice a day. And “even with Norvir,” he says, “Aptivus will lower other PIs’ levels,” so don’t combine it with other PIs (the drugmakers are working on that issue). Aptivus also caused liver toxicity in studies, so Glesby says to watch liver enzymes. On the bright side, Grossman calls the new PI’s lipid profile “better than you’d think, considering you’re boosting it with four Norvirs.”

One solution to the Norvir problem would be to better the booster. A soon-to-be-released Norvir tablet may reduce the capsule version’s GI effects. The new pill isn’t expected to tackle lipid lifts, “but you never know,” says Grossman. “Changing drug delivery [from cap to tab] can change absorption—and that can change lots of things.” Good news for the many who take Kaletra—it’s being refashioned as a tablet, too.

Some HIVers solve PI lipid problems with Reyataz (atazanavir). A recent study showed that switching from other PIs to Reyataz lowered lipids.

There are some other PIs in the pipeline, though most are in preclinical trials, and it’s too early to tell whether they will need boosting. Grossman says researchers aren’t obsessed with finding the perfect PI. “I think we’ve decided to move on to other drug classes,” he says. “Entry inhibitors—now available orally—are looking particularly good.” Class is in session.  


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dhsd777
    san diego
    California


    koffeeboss
    Tucson
    Arizona


    Heartland4now
    Tacoma
    Washington


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.